Professional background

Dr John-Paul Westwood specialises in haemostasis and thrombosis, including thrombotic microangiopathies (TTP & aHUS), immune thrombocytopenia (ITP), and bleeding disorders. He is also the UCLH venous thromboembolism (VTE) lead, and helps run the UCLH anticoagulation service and UCLH Haemophilia Centre. He completed an MD at UCL investigating the role of complement in a variety of disorders, including TTP.

Research interests

  • Clinical trials in non-malignant haematology, including TTP and ITP.


Immune thrombocytopenia in adults: A single-centre review of demographics, clinical features and treatment outcomes. Woolley P, Newton R, Mc Guckin S, Thomas M, Westwood JP, Scully MA.Eur J Haematol. 2020 Sep;105(3):344-351. doi: 10.1111/ejh.13456. Epub 2020 Jun 19.

Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Vendramin C, Thomas M, Westwood JP, Scully M.TH Open. 2018 Sep 26;2(3):e329-e333. doi: 10.1055/s-0038-1672187. eCollection 2018 Jul.

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura. Stubbs MJ, Low R, McGuckin S, Newton R, Thomas M, Westwood JP, Shah R, Cheesman S, Scully MA. Br J Haematol. 2019 Jun;185(5):912-917. doi: 10.1111/bjh.15874. Epub 2019 Mar 28.

Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Alwan F, Vendramin C, Liesner R, Clark A, Lester W, Dutt T, Thomas W, Gooding R, Biss T, Watson HG, Cooper N, Rayment R, Cranfield T, van Veen JJ, Hill QA, Davis S, Motwani J, Bhatnagar N, Priddee N, David M, Crowley MP, Alamelu J, Lyall H, Westwood JP, Thomas M, Scully M. Blood. 2019 Apr 11;133(15):1644-1651. doi: 10.1182/blood-2018-11-884700. Epub 2019 Feb 15.

Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies. Vendramin C, Thomas M, Westwood JP, McGuckin S, Scully M.Br J Haematol. 2019 Mar;184(5):858-861. doi: 10.1111/bjh.15177. Epub 2018 Mar 12.

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Westwood JP, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, Lowe GC, Dutt T, Hill QA, Scully M. Blood Adv. 2017 Jun 26;1(15):1159-1166. doi: 10.1182/bloodadvances.2017008268. eCollection 2017 Jun 27.

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, Clark A, Lester W, Gooding R, Biss T, Dutt T, Cooper N, Chapman O, Cranfield T, Douglas K, Watson HG, van Veen JJ, Sibson K, Thomas W, Manson L, Hill QA, Benjamin S, Ellis D, Westwood JP, Thomas M, Scully M. Blood. 2017 Jul 27;130(4):466-471. doi: 10.1182/blood-2016-12-758656. Epub 2017 Jun 2.

Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Br J Haematol. 2017 May;177(3):475-480. doi: 10.1111/bjh.14564. Epub 2017 Mar 14.

The role of complement activation in COPD exacerbation recovery. Westwood JP, Mackay AJ, Donaldson G, Machin SJ, Wedzicha JA, Scully M. ERJ Open Res. 2016 Oct 19;2(4):00027-2016. doi: 10.1183/23120541.00027-2016. eCollection 2016 Oct.

A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. Vendramin C, McGuckin S, Alwan F, Westwood JP, Thomas M, Scully M. Transfusion. 2017 Jan;57(1):131-136. doi: 10.1111/trf.13877. Epub 2016 Oct 23.